Neuland team had good relationship with Karuna Team, however after the latest acquisition BMS will call the shots. BMS may have existing arrangement with other API manufactures also for the KARXT drug. Management can give some guidance in this regard in next concal. For Neuland, there is a new and bigger set of potential opportunities ahead from Bristol provided that can smoothly channelise their exisitng relationship from Karuna to Bristol which is a giant in itself.
| Subscribe To Our Free Newsletter |
